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Summary
Background The associations between disease activity and several clinical signs in vitiligo
have been described, but a widely accepted and validated scoring system is lacking.
Objectives To validate the Vitiligo Signs of Activity Score (VSAS) for physicians.
Methods Three visible clinical signs were scored on 15 body locations: confetti-
like depigmentation (c), Koebner phenomenon (k) and hypochromic areas/
borders (h). The inter- and intrarater reliability of the global VSAS and VSAS
subscores (c-VSAS, k-VSAS and h-VSAS) were tested by four and three raters
(physicians), respectively. Construct validity and feasibility were evaluated.
Results The VSAS demonstrated good inter-rater reliability, with an intraclass cor-
relation coefficient (ICC) of 087 in the first round and 090 in the second
round. The intrarater reliability ICCs were all ≥ 086. The inter-rater reliabilities
of the subscores were excellent for c-VSAS and fair for k-VSAS and h-VSAS (ICC
083, 051 and 053, respectively, in the first round). Evidence for construct
validity was provided. The completion time by the raters (median 218 min per
patient) improved during the second round (median 133 min per patient). A
limitation of the study is the low number of patients, mainly of skin phototypes
II–III, from a single tertiary centre.
Conclusions The VSAS appears to be a valid and reliable instrument to score visible
clinical signs linked to disease activity in a standardized way.
What is already known about this topic?
• Evidence exists for a possible link between several visible clinical signs in vitiligo
and disease activity.
• A widely accepted and validated scoring system to quantify these clinical signs is
lacking.
What does this study add?
• The Vitiligo Signs of Activity Score (VSAS) underwent preliminary validation and
may assist quantification of visible clinical signs linked to disease activity in a stan-
dardized way in clinical practice and trials.
What are the clinical implications of this work?
• VSAS may be used for future trials that aim to establish the clinical significance of
the specific visible clinical signs in vitiligo in a more controlled setting.
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Although the course of vitiligo is known to be cyclic, with flares
and remission, the exact rhythmicity is still unpredictable. Cur-
rently, it is well demonstrated that the depigmentation process
is linked to an immune destruction of melanocytes. Based on
these data new treatments are under development.1,2 At the
moment, there are three aims for optimal treatment of vitiligo:
(i) halting disease progression, (ii) repigmentation by stimula-
tion of melanocyte differentiation and proliferation and (iii)
prevention of relapses.3–6 For now, the clinical assessment of
disease activity at a first visit or at a specific single timepoint
relies on the presence of clinical signs such as Koebner phe-
nomenon, hypochromic areas/borders and confetti-like
lesions.7 This information can be relevant for clinical trials and
clinical practice (e.g. start a treatment to halt progression) but it
does not allow quantification of disease activity.8
Currently, available outcome measures for disease activity in
vitiligo are scarce. So far, the Vitiligo Disease Activity Index
(VIDA) score is the most frequently cited measurement instru-
ment by researchers, although it is constructed as a recall-
based patient-reported outcome measure. However, this VIDA
score was demonstrated to be unreliable.9 No validation stud-
ies on physician-reported outcome measures specifically
designed to score signs linked to disease activity in a com-
bined score have been reported so far in vitiligo.
For many years several clinical signs such as Koebner phe-
nomenon, hypochromic or trichromic areas and confetti-like
depigmentation have been suggested to be linked to disease
activity in vitiligo.10–12 Based on a recent systematic review,
evidence for a possible link was provided.7 However, the
interpretation of the literature was hampered by the lack of
uniform definitions and firmly established assessment meth-
ods to evaluate these signs. Moreover, no appropriate instru-
ment to quantify these clinical signs could be identified that
met the minimal requirements for acceptable measurement
properties (e.g. validity, reliability and responsiveness). Such
an instrument is required in clinical practice and trials. In
addition to the general need for a validated instrument to
quantify the current state of the clinical signs of disease activ-
ity this instrument is also mandatory to demonstrate the real
prognostic value of these clinical signs during future prospec-
tive trials.
The aim of this study was to assess the reliability, validity
and feasibility of a measurement instrument to assess and
quantify clinical signs linked to disease activity in vitiligo.
Materials and methods
Study design, ethics and construction of a scoring
system
This study was performed by a team of vitiligo experts on
behalf of the international Vitiligo Score Working Group and
was supported by the Vitiligo European Task Force and the
Vitiligo Global Issues Consensus Conferences (VGICC) group.
The work was presented and discussed during two international
special interest vitiligo meetings: the Vitiligo International
Symposium, Detroit, 10 November 2018; and the VGICC meet-
ing at the World Congress of Dermatology, Milan, 10 and
14 June 2019.
The design of the scoring instrument was initiated, evaluated
(during clinic practice) and modified (layout-related correc-
tions, grading more specified) in a preparatory phase at the
Ghent University Hospital (N.vG.). Several key elements were
considered during this phase such as clinical relevance, simplic-
ity, feasibility and availability for use in both clinical trials and
daily practice. The clinical relevance of items included in the
VSAS was supported by the opinion of vitiligo experts provided
during the VGICC meeting in Rome, 2016 (Appendix S1; see
Supporting Information). Based on this concept and a systematic
review, three items were considered by the team of European
vitiligo experts (N.vG., K.E., A.W., T.P.) to be worthwhile to
evaluate within this study. The selection of items was based on
discussions by phone and a decisive face-to-face meeting (Nice,
France, 16 August 2018; N.vG., K.E., A.W., T.P.). The selected
items were (i) confetti-like depigmentation, (ii) Koebner phe-
nomenon and (iii) hypochromic areas/borders. In addition, the
definitions of each sign were discussed. The term ‘trichrome
vitiligo’ was not included based on current confusion related to
definition and uncertainties of its relevance.7 It was decided by
the scoring team not to include ‘inflammatory borders’ as an
item. The main reasons were that the prevalence of inflamma-
tory vitiligo is thought to be very low and that the remaining
questions related to its exact definition and assessment need to
be clarified first in future trials.
The main numerical output (score) obtained by this mea-
surement instrument was the overall VSAS. This score was
based on the presence of visible clinical signs within 15 pre-
defined body locations (Figure 1). Most of the locations are
based on the anatomical regions of the Vitiligo Extent Score
(VES), representing classical anatomic units.13,14 Evaluation of
all 15 body locations was considered to be important, as viti-
ligo can be active in limited or several areas. The presence of
at least one of the three signs in a specific area was coded 1,
with a score of 0 if none of the three signs was present,
resulting in a score between 0 and 15. Each body area has the
same impact on the total score. A similar score (0–15) was
performed for each clinical sign separately generating sub-
scores: confetti-like depigmentations (c-VSAS), Koebner phe-
nomenon (k-VSAS) and hypochromic areas/borders (h-VSAS)
(Figures 1 and 2).
Within this study, in addition to the subscores an option for
grading the degree of each clinical sign was included (grade 1–
3; Figure 2), reflecting the intensity per area. This intensity was
measured as the estimated number of clinical signs around a
representative lesion for c-VSAS and the estimated number per
demarcated area for k-VSAS and h-VSAS, with grades 1–3 corre-
sponding overall to ‘somewhat present’, ‘clearly present’ or
‘very clearly present’. Based on the grading per area, in addition
one global (total body) grade per sign was assigned (considered
as the grade that was most evident on average for a specific
sign). Both the VSAS subscores and grading per sign were con-
sidered as secondary outcomes of the measurement instruments.
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Scoring was introduced during a training session (by
N.vG.) of about 10–15 min, which was supported by several
clinical photographs and formulated definitions, both serving
as a reference for the scoring.
For each visible clinical sign (Figure 2) the definitions formu-
lated were as follows. (i) Confetti-like depigmentations: ‘confetti-like
depigmentations are grouped small/pinpoint-sized hypo- and
depigmented macules.’12,14 (ii) Koebner phenomenon (definition
included in two papers):15,16 ‘Koebner type 2B is considered to be
positive if at clinical examination and Wood’s light inspection,
depigmentations are present and clearly induced by trauma (linear,
punctiform, crenate)’.15,16 (iii) Hypochromic areas/borders (translated
from a discussed clinical description based on examples of clinical
pictures): ‘hypochromic areas/borders are ill-defined borders or
hypopigmented areas located at the contours of the vitiligo lesion’.
The study was approved by the ethics committee (refer-
ence number Ghent: B670201421409). Written informed
consent was obtained from all patients for the use of the
pictures within the scoring sessions. The COSMIN checklist
was used as guidance for designing and reporting our
study.17–19
Raters and participants
The raters were all vitiligo experts from different university
clinics in Europe. Scoring of the clinical signs was done inde-
pendently on a standardized form (Figure 1). Independence of
rating was ensured by using separate computers and scoring
sheets for each rater and by providing instructions for assess-
ment (no interindividual discussion allowed).
Figure 1 Measurement instrument used to score the Vitiligo Signs of Activity Score (VSAS) and subscores (c-VSAS, k-VSAS, h-VSAS) within 15
body locations, including minor modifications. The overall VSAS is based on the presence of (at least one) visible clinical signs within the 15
predefined areas resulting in a score between 0 and 15. A similar score (0-15) can be performed for each clinical sign separately generating the
subscores: confetti-like depigmentations (c-VSAS), Koebner phenomenon (k-VSAS) and hypochromic areas/borders (h-VSAS). If a clinical visible
sign is present one can add/write in each demarcated areas the applicable abbreviation for each sign (C, K, H) and add optionally the most
applicable grade for that area (e.g. C1; C2; C3; K1; K2; K3; H1, H2, H3). Based on the grading per area, in addition one ‘global grade’ (total
body grade) per sign can be assigned, which can be considered as the grade that is most evident on average for a specific sign.
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Patients were recruited at the Ghent University Hospital
(Ghent, Belgium) and were selected at random from a group
of voluntary clinically diagnosed patients with (nonsegmental)
vitiligo, who were divided before randomization into different
groups based on a global estimation of the extent of vitiligo
(by N.vG.). These patients were photographed in a standard-
ized manner during routine clinical practice, and a set of gen-
erated ultraviolet system-based images was subsequently used
for the scoring sessions. Overlap of this set exists with the set
used in a previous study.20
Reliability
The inter-rater reliability was assessed by comparing both the
VSAS and the subscores per clinical sign (c-VSAS, k-VSAS,
h-VSAS) and grading per item within each area (grade 1–3)
between all raters. For the evaluation of the intrarater reliabil-
ity, measurements were repeated on the same series of pho-
tographs, which were randomized in sequence using Research
Randomizer (https://www.randomizer.org), with an interval
of at least 2 weeks between rating sessions.
Validity
Face validity was assessed to evaluate the degree to which the
items of the instrument are an adequate reflection of the con-
struct to be measured, and was based on expert opinions and
the literature.7,14,19
Construct validity was evaluated based on testing against four
hypotheses (formulated by two investigators) as no gold standard
exists (Appendix S2; see Supporting Information). Sufficient evi-
dence for construct validity was assumed if ≥ 75% of the
hypotheses were in accordance with the results. All hypotheses
include a comparison (correlation or predictions) between the
median VSAS of all raters and an expert Physician’s Global Assess-
ment (PGA) score for clinical disease activity (performed by one
expert, who was not involved in the scoring sessions). This PGA
score included a five-point scale ranging from no disease activity
to very severe disease activity.
Feasibility
The completion time was recorded by each rater to evaluate
the feasibility of this scoring system. This scoring included










Figure 2 Chart for grading each sign (grade 1–3) in the Vitiligo Signs of Activity Score (VSAS), translated from formulated definitions and
photographic examples used within the context of this study. The grading reflects estimation of the intensity of each clinical sign within a specific
area. For c-VSAS (confetti-like lesions) this is the estimated number of confetti-like depigmentations around a representative lesion (grade 1, < 10;
grade 2, 10–50; grade 3, > 50). For k-VSAS (Koebner phenomenon) and h-VSAS (hypochromic areas/borders) this is the presence (estimated
number of signs) per demarcated area: grade 1, 1; grade 2, 2–5; grade 3, > 5. The grades correspond overall to ‘somewhat present’ (grade 1),
‘clearly present’ (grade 2) or ‘very clearly present’ (grade 3). The clinical photographs represent an example of each sign. Based on the grading
per area, in addition one ‘global grade’ (total body grade) per sign can be assigned, which can be considered as the grade that is most evident on
average for a specific sign.
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two steps: completion of the instrument (step 1) and calcula-
tion of the score (step 2). The total completion time was cal-
culated based on the total timing of the two steps, or by the
sum of the two steps separately.
Statistics and data analysis
Inter- and intrarater reliability were assessed using the two-way
random (or two-way mixed for intrarater), absolute-agreement,
single-measures intraclass correlation coefficient (ICC). The fol-
lowing guidelines for the interpretation of the ICC were used:
< 04 was considered poor, 04–059 fair, 06–074 good and
≥ 075 excellent.21 For the correlation as included in the first
hypothesis to test construct validity (Appendix S2; see Support-
ing Information), Spearman’s rho correlation was used. Com-
parison of completion times (average ranking) between the first
and second rounds was evaluated by Wilcoxon signed-rank
tests. All analyses were performed using SPSS Statistics version
25 (IBM, Armonk, NY, USA).
Results
Raters and participants
The first scoring round was performed by four raters and the
retest by three raters with an interval of approximately 2
months. In total, 247 ultraviolet pictures from 23 patients
with vitiligo were included for the scoring. These patients had
Fitzpatrick skin type II (two), III (19), IV (one) and V (one);
12 were female and 11 male. The total body surface area
affected (assessed by VES) varied between the patients (range
013–427%, median 228%, mean 595%). The mean age at
inclusion was 36 years (median 40, range 17–64) and the
mean age at onset was 257 years (median 25, range 15–45;
n = 19).13 At least one clinical sign was present in 17 of 23
cases (74%). Signs were considered ‘present’ if they were
reported by at least three of the four raters. Presence of con-
fetti-like depigmentations was recorded in 15 of 23 (grade 1
in seven, grade 2 in five and grade 3 in three), Koebner phe-
nomenon in nine of 23 (grade 1 in seven and grade 2 in
two) and hypochromic areas/borders in 15 of 23 (grade 1 in
14, grade 2 in one). Only two of 23 cases (9%) showed one
isolated sign (both with hypochromic areas/borders), eight of
23 cases (35%) showed two signs (confetti-like depigmenta-
tions with Koebner phenomenon, and hypochromic areas/
borders with confetti-like depigmentations) and seven of 23
cases (30%) showed all three clinical signs.
Reliability
Inter-rater reliability
The median overall VSAS (first round) was 4 [range 0–13,
interquartile range (IQR) 1–8]. Figure 3 shows a scatter plot
illustrating the distribution of the overall VSAS in mean rank
order of all cases. The median scores (first round) for con-
fetti-like depigmentations, Koebner phenomenon and
hypopigmented areas/borders separately (c-VSAS, k-VSAS and
h-VSAS) were 3 (range 0–12, IQR 0–7), 1 (range 0–8, IQR
0–8) and 1 (range 0–11, IQR 0–2), respectively. Table 1 lists
the ICCs with 95% confidence intervals (CIs) of the overall
score (VSAS) and each subscore (c-VSAS, k-VSAS and h-VSAS).
The ICC inter-rater reliabilities for the overall score (VSAS)
were excellent for both the first and second rounds (ICC 087
and 090, respectively). Similarly, the confetti-like depigmen-
tation subscore (c-VSAS) also reached excellent ICC agree-
ments. Inter-rater reliabilities for the Koebner phenomenon
(k-VSAS) and hypochromic areas/borders (h-VSAS) subscores
were fair (ICC 051 and 053) in the first round, while this
improved to good agreement for Koebner phenomenon in the
Figure 3 Vitiligo Signs of Activity Score
(VSAS) scatter plot illustrating the distribution
of the overall VSAS (y-axis) by four raters.
The x-axis presents the rank order of the
mean VSAS of all raters.
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second round (ICC 072, 95% CI 052–086). Inter-rater
agreements for grading the severity of each item within the
involved areas (grade 1–3) were excellent for confetti-like
lesions (ICC 083, 95% CI 071–092), and fair for Koebner
phenomenon (ICC 056, 95% CI 035–076) and hypochro-
mic areas/borders (ICC 051, 95% CI 031–071).
Intrarater reliability
Test–retest measurements showed excellent intrarater reliability
(ICC ≥ 086) for the overall VSAS (Table 1 and Figure 4).
Good median intrarater reliability was also found for the sub-
scores confetti-like lesions (c-VSAS, ICC 089), Koebner phe-
nomenon (k-VSAS, ICC 063) and hypochromic areas/borders
(h-VSAS, ICC 073) (Table 1).
Validity
Face validity for the items included in the VSAS was supported by
the opinion of vitiligo experts (Appendix S1; see Supporting
Information) and a systematic review.7,14 Sufficient evidence for
construct validity was provided, as three of the four hypotheses
for construct validity were confirmed (Appendix S2; see Support-
ing Information). A strong positive monotonic correlation (me-
dian r = 075) was found between the median VSAS of the four
raters per included case and the expert’s PGA scores (Table 2 and
Figure 5). The correlations (Spearman rho) between each rater
separately and the expert’s PGA scores were 069, 074, 068 and
068, respectively. For the second and fourth hypotheses the cut-
off values of 50% were widely reached (78% and 75%, respec-
tively; median of all raters). The third hypothesis was not
reached, which can be explained by the low number of cases with
a score of 0 (mean number of cases 55, median 6) and the fact
that the expert rater was not informed about the predefined defi-
nitions for use of the instrument. A PGA score of ‘not present’
was selected only twice by the expert.
Feasibility
The median total completion time for the scoring and calcula-
tion of score in the first round was 138 s per patient (range
7–450). Significant improvement of the average ranking of
completion times was observed in the second round for two
of three raters (P-value from Wilcoxon signed-rank tests <
0001). The median total completion time in the second
round was 93 s per patient (range 10–323).
The median completion times of the instrument and score
calculation separately in the first round (assessed by two
raters) were 91 s per patient (range 3–383) for filling in the
instrument (15 anatomical areas) and 18 s per patient (range
2–120) to calculate the scores.
Table 1 Assessing inter- and intrarater reliability
Round Number of raters Score Estimated ICC (95% CI)
Inter-rater reliability









1 vs. 2 3 VSAS Rater 1: 086 (070–094)
Rater 2: 095 (088–098)
Rater 3: 090 (072–096)
c-VSAS Rater 1: 089 (075–095)
Rater 2: 095 (089–098)
Rater 3: 089 (073–096)
k-VSAS Rater 1: 063 (029–082)
Rater 2: 088 (075–095)
Rater 3: 058 (022–080)
h-VSAS Rater 1: 060 (026–081)
Rater 2: 089 (075–095)
Rater 3: 073 (047–087)
The sample size was 23 patients for all assessments. CI, confi-
dence interval; ICC, intraclass correlation coefficient; VSAS, over-
all Vitiligo Signs of Activity Score; c-VSAS, VSAS for confetti-like
depigmentations; k-VSAS, VSAS for Koebner phenomenon type
2B; h-VSAS, VSAS for hypochromic areas/borders.
Figure 4 Bland–Altman plot illustrating the
variation in Vitiligo Signs of Activity Score
(VSAS) scores between the first and second
scoring rounds (test–retest), which is a
measure of the intrarater reliability. The
intrarater intraclass correlation coefficient of
the median of all raters was 090. The
coloured dots represent the different raters.
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Discussion
In this study we evaluated the inter- and intrarater reliability,
validity and feasibility of VSAS, a tool to quantify visible clini-
cal signs linked to disease activity in a standardized way. This
can be important for clinical trials (e.g. evaluating immune-
modulating agents) and clinical practice (e.g. selecting specific
treatments).1,2,8 The main strength of the VSAS is that a repro-
ducible quantification of signs linked to disease activity in viti-
ligo can be proposed. The conversion into a numerical output
might improve the monitoring of patients and communication
between physicians. Results for reliability exceeded the cutoff
point of acceptable inter- and intrarater reliability, and suffi-
cient evidence for construct validity was provided. Based on
the improved completion time in the second round we
demonstrated that training seems to be useful.
Future stratification of the score is important to translate it
into clinically meaningful categories (e.g. mild to very severe)
and to define possible thresholds for the scores. The grading
of each sign per involved area (grade 1–3) may be important
to investigate in more detail before definitive implementation
in the clinic or trials. This grading needs further validation
especially related to its relevance. For now, it can be added as
an option that will in particular be useful for studies investi-
gating the prognostic significance of the separate signs in
more depth. Within this context, combination with the
evaluation of disease progression over time might also be
important (comparison of two timepoints, in general based
on clinical photographs). This assessment can complete the
scoring of disease activity. Future studies combining the quan-
tification of disease activity signs with disease progression will
therefore be required to provide more insight into the prog-
nostic value of the obtained overall score, subscores and grad-
ing separately. To perform this type of study a standardized
scoring system (such as the VSAS score) is required.
A strength of this measurement instrument is that it can be
used during a single consultation for all patients (of all ages
and with its segmental subtype). However, for the interpreta-
tion of the calculated score in segmental vitiligo we need to
keep in mind the generally more limited number of locations
that are involved compared with nonsegmental vitiligo. There-
fore, interpretation of the scores may better be restricted to
the respective subtypes.
Limitations of this study are the limited number of cases,
from a single tertiary centre, and the limited variations of skin
phototype (mainly II–III) of the included patient population.
This limits possible generalization of the results. Photographs
were taken during routine practice, which might be considered
an advantage, as the quality of the pictures represents a real-life
or routine situation. However, this also influenced the reduced
availability of skin details (zoomed-in pictures), which might
have negatively influenced the reliability. Live scoring may fur-
ther improve the reliability (increase the visibility of the signs),
although the feasibility aspects (e.g. complexity and timing)
within this environment still need to be evaluated.
More studies within the international network are definitely
required, with more investigators and raters, and on a larger
cohort of patients of different origins to evaluate the compre-
hensibility of the scoring system and to reach a final consensus.
Moreover, future studies are needed to evaluate the responsive-
ness of the VSAS and VSAS subscores, the exact value of each
clinical sign separately in the prediction of the global disease
Table 2 Spearman correlations between overall Vitiligo Signs of Activity
Score and Physician’s Global Assessment expert score in round 1
Rater Spearman’s rho P-value
1 069 < 0001
2 074 < 0001
3 068 < 0001
4 068 < 0001
Figure 5 Box plots showing increasing
Vitiligo Signs of Activity Score (VSAS) for
higher Physician’s Global Assessment (PGA)
scores. Correlations between the VSAS scores
and PGA expert score showed significant
P-values (P < 0001) for all raters, using
Spearman’s rho.
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published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
British Journal of Dermatology (2020)
Vitiligo Signs of Activity Score (VSAS), N. van Geel et al. 7
activity, and the relevance of VSAS from the patient perspective
and/or its associations with patient-reported outcomes. To
improve future implementation and accessibility a software
application is currently under construction.
In conclusion, we demonstrated the reliability, validity and
completion time of the VSAS. This measurement instrument
enables a standardized registration of clinical signs linked to dis-
ease activity in vitiligo. Moreover, it can be used for future trials
that aim to establish the clinical significance of the specific visible
clinical signs in vitiligo in a more controlled setting. However,
complementary studies will be required within different interna-
tional settings to get more insight into the value of this instru-
ment. These should measure content and construct validity,
including evaluation of the clinical relevance of the suggested
grading and evaluation of the responsiveness, and translation of
the score into categories (e.g. mild to very severe).
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